Skip to content

Dr. Gearóid Tuohy

GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.

A prospective cohort study of IRD patients report the frequency and distributions of ophthalmic surgical procedures at the Wilmer Eye Institute.

Researchers at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, has reported that an estimate cohort of one-third of inherited retinal dystrophy (IRD) patients had… Read More »A prospective cohort study of IRD patients report the frequency and distributions of ophthalmic surgical procedures at the Wilmer Eye Institute.

AI responses (“chatbots”) compare favourably against ophthalmic specialists (human) using a “large language model” [LLM] for retinal and glaucoma diseases.

Researchers at the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, has reported an artificial intelligence (AI) tool, as a “large… Read More »AI responses (“chatbots”) compare favourably against ophthalmic specialists (human) using a “large language model” [LLM] for retinal and glaucoma diseases.

Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).

Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.

Researchers at the Department of Ophthalmology, at The Hebrew University of Jerusalem, have reported a new comprehensive analysis on Best disease patients, aimed to document… Read More »Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.